Shih-Min Wang

Title: Innovations in Prostate Cancer Treatment by Shih-Min Wang

Introduction

Shih-Min Wang is a notable inventor based in Taoyuan, Taiwan. He has made significant contributions to the field of medicine, particularly in the area of targeted therapies for prostate cancer. His innovative work focuses on the development of a novel precursor for radioisotope labeling, which is crucial for the diagnosis and treatment of prostate cancer.

Latest Patents

Wang holds a patent for a groundbreaking invention titled "PSMA targeted radiotherapy medicine and preparation method thereof." This invention features a unique precursor designed for radioisotope labeling with ligands that specifically bind to prostate-specific membrane antigen (PSMA). The pharmacophore of the PSMA inhibitor consists of three molecules: glutamic acid, urea, and lysine. These components are linked by three variable linkers, which enhance the pharmacological activity of the PSMA inhibitor. The invention allows for labeling with radioactive nuclei such as Ga-67, Ga-68, In-111, Lu-177, Cu-64, or Y-90 through a chelating agent. This advancement facilitates imaging analysis of human tumor models of prostate cancer and serves as a PSMA-targeted radioligand therapy for prostate cancer diseases.

Career Highlights

Shih-Min Wang is affiliated with the National Atomic Research Institute, where he continues to advance his research in radiotherapy and cancer treatment. His work has garnered attention for its potential to improve patient outcomes in prostate cancer diagnosis and therapy.

Collaborations

Wang collaborates with fellow researcher Sheng-Nan Lo, contributing to the development of innovative solutions in the field of cancer treatment.

Conclusion

Shih-Min Wang's contributions to prostate cancer treatment through his patented innovations highlight the importance of targeted therapies in modern medicine. His work exemplifies the potential of scientific research to transform healthcare and improve patient lives.